Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers Impact on the Response to Erlotinib in First-Line EGFR-Mutated NSCLC
2009-017063-42Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoints: Association between treatment efficacy and EGFR activating mutations, Progression-free survival (PFS) and 1 more. Started Dec 2016; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-017063-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017063-42.